当レポートは、処方薬分野におけるAmgen
Inc.の実績と予測、世界的企業戦略、ポートフォリオ、パイプライン、財務実績、主力製品の1〜6年間の売上予測などをまとめ、製品別、治療分野別、ライフサイクル別、地域別、分子タイプ別に検証し、概略以下の構成でお届けします。
Abstract
Introduction
This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs
Features And Benefits
• Gain insight into Amgen' s strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Amgen over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company' s prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your Key Questions Answered
• Benchmark Amgen' s performance against key rivals in the prescription pharmaceutical sector
• Assess the importance of the recently approved Prolia/Xgeva (denosumab) in shaping Amgen' s future sales performance
Table of Contents
Executive Summary
Key findings
Amgen prescription pharma sales outlook
Amgen financial outlook
Key developments
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Sales Analysis
Financial Analysis
Product Analysis
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
[Missing title]
Key franchise hit by damaging clinical trial data in 2007 - Aranesp sales decline significantly over 2006-10
Amgen 2007 cost cutting has allowed for operating profit growth despite recent top-line sales decline
Therapeutic proteins decline; a switch to growth through MAbs
Restructuring initiatives during 2007-08 have left Amgen in a strong fiscal position
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Abgenix acquisition
Alantos and Ilypsa
Bergamo - tapping into the high-growth Brazilian market
Current corporate structure
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004-16
Product analysis
Product analysis, 2004-10
Product analysis, 2010-16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010-16
Core analysis, 2010-16
Expiry analysis, 2010-16
Launch/core/expiry configuration, 2010-16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2004-10
Operating cost ratio and profit margin analysis, 2004-10
Operating cost ratio and profit margin analysis, 2010-16
Operating costs and profit analysis, 2010-16
PRODUCT ANALYSIS
Overview
Neulasta
Xgeva
Enbrel
Aranesp franchise
Epogen franchise
Prolia
Amgen pipeline overview
Appendix
References
Abbreviations
Exchange rates
